These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30522890)

  • 41. Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.
    Naga D; Parrott N; Ecker GF; Olivares-Morales A
    Mol Pharm; 2022 Jul; 19(7):2203-2216. PubMed ID: 35476457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies.
    Grabowski T; Reijers JAA; Burmańczuk A; Chełmońska-Soyta A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):585-589. PubMed ID: 30810916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties.
    Hu S; Datta-Mannan A; D'Argenio DZ
    MAbs; 2022; 14(1):2056944. PubMed ID: 35491902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies.
    Glassman PM; Balthasar JP
    Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
    Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
    AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
    Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
    Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
    Huang HW; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):621-638. PubMed ID: 37947924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
    Li Z; Li Y; Chang HP; Yu X; Shah DK
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
    Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
    Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.
    Avery LB; Wade J; Wang M; Tam A; King A; Piche-Nicholas N; Kavosi MS; Penn S; Cirelli D; Kurz JC; Zhang M; Cunningham O; Jones R; Fennell BJ; McDonnell B; Sakorafas P; Apgar J; Finlay WJ; Lin L; Bloom L; O'Hara DM
    MAbs; 2018; 10(2):244-255. PubMed ID: 29271699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
    Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
    Zhao J; Cao Y; Jusko WJ
    Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
    Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
    Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologically-based simulation modelling for the reduction of animal use in the discovery of novel pharmaceuticals.
    Thomas S
    Altern Lab Anim; 2009 Nov; 37(5):497-511. PubMed ID: 20017579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.